Principal Investigator
Peter Hosein
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231247
Clinical Trial Summary
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Stomach and Esophageal Cancer
Contact Information
Phone Number
305-243-2647